Product category:
Cell/tissue handling and counting
News Release from: Microbix Biosystems
Edited by the Laboratorytalk Editorial
Team on 23 June 2004
Flu technology attracts interest
Microbix enters exclusive review and negotiation period for proprietary influenza virus yield enhancement technology
Microbix Biosystems has entered into an exclusive review and negotiation period with a major international influenza vaccine producer for its virus yield enhancement technology for which patents are pending Microbix will receive monthly payments during the exclusive review and negotiation period, and US$1 million upon confirmation that its technology will deliver a four fold yield improvement to influenza vaccine production
This article was originally published on Laboratorytalk on 20 Mar 2003 at 8.00am (UK)
Related stories
Double anniversary at Focus
Supplier of one quarter of the world's haematology analysers celebrates its twentieth birthday, while its parent company celebrates its fiftieth
Merger of HTP operations
"With a combined instrumentation and biochemistry team we can respond faster and more flexibly to the assaying demands of current and future customers"
If successful, Microbix will receive further milestone and royalty payments.
"Influenza is the first application for Microbix's yield enhancement technology platform," said William Gastle, president and CEO, "and while no definitive license agreement is assured, this is a promising step in the commercialisation of the technology".
Microbix's yield enhancement technology is the second significant product for the company to reach the licensing stage and follows the successful partnering in November 2002 of the company's generic version of urokinase trademarked ThromboClear, which is a blood clot dissolving biopharmaceutical.
Microbix specialises in developing proprietary biological technologies.
The company has a core technology platform based on cell biology, purification and characterisation of viruses and proteins.
Microbix's objective is to develop and, through global marketing partners, commercialise those technologies that can be brought to market in less than five years.
• Microbix Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
